The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis
References (100)
Classification of chronic viral hepatitis: a need reassessment
J Hepatol
(1991)- et al.
Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis
J Hepatol
(1992) - et al.
Randomized trial of lymphoblastoid α-interferon in chronic hepatitis C. Effects on inflammation, fibrogenesis and viremia
J Hepatol
(1993)et al.Prediction of sustained remission of chronic hepatitis C after a 12-month course of alfa interferon
J Hepatol
(1994) - et al.
α-Interferon in the treatment of chronic viral hepatitis: effects on fibrogenesis serum markers
J Hepatol
(1993) - et al.
Lymphoblastoid α-interferon for chronic hepatitis C: a randomized controlled study
Am J Gastroenterol
(1993) - et al.
Transfusion-associated chronic hepatitis C: alpha-n1 interferon for 6 vs. 12 months
J Hepatol
(1996) - et al.
Histological outcome of chronic hepatitis C treated with a 12-month course of lymphoblastoid alfa interferon
Liver
(1993) - et al.
Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial
Hepatology
(1995) - et al.
Recombinant human α-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France
Hepatology
(1991) - et al.
The use of recombinant interferon alfa-2b in elderly patients with anti-HCV-positive chronic active hepatitis
J Am Geriatr Soc
(1993)
Treatment of chronic hepatitis C with recombiannt interferon alfa
Ital J Gastroenterol
Randomized trial of effect of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis
Lancet
Treatment of chronic hepatitis C with recombinant interferon alfa-2b for nine months
Gut
A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis
N Engl J Med
A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis
J Hepatol
Interferon alpha-2b treatment of chronic post-transfusion non-A non-B/C hepatitis: long-term outcome and effect of increase interferon doses in non-responders
Scand J Infect Dis
A phase II study of interferon alfa-2b treatment of anti-HCV positive and negative chronic NANB hepatitis: interim analysis
J Hepatol
Alpha-interferon treatment of chronic hepatitis C: a controlled, multicentre, prospective study
Digestion
Treatment of cryptogenic chronic liver diseases with recombinant alpha-2a interferon. Preliminary results of a randomized controlled clinical trial
Ann Ital Med Int
Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C
Ann Intern Med
High dose interferon treatment in chronic hepatitis C
Gut
Interferon alfa for chronic hepatitis C in haemophiliacs
Gut
High-dose interferon alfa-2A for the treatment of chronic hepatitis C
Ann Pharmacother
Recombinant interferon-α and ursodeoxycholic acid versus interferon-α alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up
Am J Gastroenterol
Treatment of chronic hepatitis C with hig-dose interferon a-2b: a multicenter study
Dig Dis Sci
Detection of hepatitis C virus RNA in patients with chronic hepatitis C virus infections during and after therapy with alpha interferon
Antimicrob Agents Chemother
Viral and host factors that contribute to efficacy of interferon-α2a therapy in patients with chronic hepatitis C
Dig Dis Sci
A randomized controlled trial of human lymphoblastoid interferon in patients with compensated type C cirrhosis
Am J Gastroenterol
Efficacy of longterm interferon treatment in chronic liver disease evaluated by sensitive polymerase chain reaction assay for hepatitis C virus RNA
Gut
Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis
Hepatology
The hepatology of hepatitis C
Hepatology
The nomenclature of chronic active hepatitis: an obituary
Gastroenterology
Interferon-α for chronic hepatitis C: an analysis of pretreatment clinical predictors of response
Hepatology
Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment
Hepatology
Long-term follow-up of chronic post-transfusion non-A, non-B hepatitis: clinical and histological outcome
Liver
Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis
Hepatology
Long-term follow-up of chronic hepatitis non-A, non-B with special reference to hepatitis C
Liver
Long-term mortality after transfusion associated non-A, non-B hepatitis
N Engl J Med
Non-A, non-B post-transfusion hepatitis. Looking back in the second decade
Ann Intern Med
Chronic non-A, non-B hepatitis developed after transfusions, illicit self-injections or sporadically. Outcome during long-term follow-up — a comparison
Liver
Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis
Gastroenterology
Serum markers of hepatic fibrogenesis in chronic hepatitis type C treated with alfa-2a interferon
Liver
Prolonged treatment (18 months) of chronic hepatitis C with recombinant α-interferon in comparison with a control group
J Hepatol
Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates
J Hepatol
Treatment of chronic sporadic-type non-A, non-B hepatitis with lymphoblastoid interferon: gamma GT levels predictive for response
Dig Dis Sci
Randomized, double-blind, placebo-controlled trial of eight-week course of recombinant α-interferon for chronic non-A, non-B hepatitis
Dig Dis Sci
Low-dose interferon in chronic hepatitis non-A/non-B: effects on quantitative liver function and structure in a randomized, controlled multicenter trial
Clin Invest
Long-term titrated recombinant interferon-α2a in chronic hepatitis C: a randomized controlled trial
J Viral Hep
High doses of recombinant α-interferon or gamma-interferon for chronic hepatitis C: a randomized, controlled trial
Hepatology
Histologically advanced chronic hepatitis C treated with recombinant alpha-interferon: a randomized placebo-controlled double-blind cross-over study
J Hepatol
Cited by (75)
Paediatric hepatitis C virus infection and its treatment: Present, past, and future
2019, Arab Journal of GastroenterologyCitation Excerpt :The magnitude of the improvement with combination therapy was impressive, with a two-fold improved response rate in the 48-week combination regimen when compared with IFN alone for 48 weeks. Because of the worldwide prevalence of HCV and the associated mortality with cirrhosis, these results represented a major impact in the treatment of HCV infection [91,92] The advantage of combination therapy that it helped subgroups of patients in whom treatment has been unsuccessful, such as patients with HCV genotype 1 infection, high pretreatment viral burdens, or advanced fibrosis or cirrhosis [88]. In 2011, the FDA has approved using the combination of peginterferon alfa-2a and ribavirin for young patients with chronic hepatitis C aged 5 to 17 years.
Long-term histological change in chronic hepatitis C patients who had received peginterferon plus ribavirin therapy with sustained virological response
2019, Journal of the Formosan Medical AssociationCitation Excerpt :A combination of the resolution of hepatic inflammation and the actual regression of fibrosis may contribute to the early detection of the regression of liver fibrosis.18 The prolonged course of hepatitis C infection17 leads to questions regarding how the regression evolves and how the changes in fibrotic stage occur with time. It is important to evaluate the long-term outcomes and to elucidate whether viral eradication is associated with persistent histological benefits.
Hepatitis C virus antiviral therapy in patients with cirrhosis
2004, Gastroenterology Clinics of North AmericaResolution of hepatic fibrosis as a consequence of interferon therapy for hepatitis C
2003, Frontiers in Viral Hepatitis